All In Biotech

NDA 205109 · Vifor Fresenius

Velphoro

Ferric Oxyhydroxide · Oral · Phosphate Binder

Last checked: Nov 19, 2026Latest source record: Oct 13, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2013

Nov 27, 2013

Approved uses

3

Original approval plus efficacy supplements

Registered trials

2

1 Phase 3, 0 recruiting

FAERS reports

3,046

2,193 serious, 1,293 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 26, 2026.

Velphoro is indicated for the control of serum phosphorus levels in adults and pediatric patients 6 years of age and older with chronic kidney disease (CKD) on dialysis. Velphoro is a phosphate binder indicated for the control of serum phosphorus levels in adult and pediatric patients 6 years of age and older with chronic kidney disease on dialysis. ( 1 )

Mechanism: In the aqueous environment of the GI tract, phosphate binding takes place by ligand exchange between hydroxyl groups and/or water in sucroferric oxyhydroxide and the phosphate in the diet. The bound phosphate is eliminated with feces. Both serum phosphorus levels and calcium-phosphorus product levels are reduced as a consequence of the reduced dietary phosphate absorption.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

2 products under this application
  • VELPHORO · FERRIC OXYHYDROXIDE EQ 500MG IRON · TABLET, CHEWABLE, ORAL · Prescription
  • VELPHORO · FERRIC OXYHYDROXIDE EQ 250MG IRON · TABLET, CHEWABLE, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Ferric Oxyhydroxide" as an intervention, any sponsor and status, largest first.

All 2 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • death1,146
  • diarrhoea328
  • nausea100
  • constipation90
  • hospitalisation88
  • vomiting87
  • faeces discoloured84
  • drug intolerance68
  • abdominal discomfort63
  • off label use61
  • product taste abnormal60
  • abdominal pain53

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
201425
2015131
2016135
2017259
2018284
2019479
2020661
2021320
2022114
2023105
2024195
2025216
2026122

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Velphoro (Sucroferric Oxyhydroxide)

2024 spending

$438M

Beneficiaries

38,351

156,980 claims

Per beneficiary

$11,432

$17.29 per unit

View as table
YearSpending
2020$343,032,075
2021$380,608,096
2022$426,893,782
2023$465,812,435
2024$438,436,195

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1 on PubMed

Sponsor: Vifor Fresenius

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.